Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2016 · 10-Q
Revenue$7.42M$7.42M+21.7% vs Q2 2015 Net Income-$82.67K-$82.67KN/M vs Q2 2015 EPS Diluted$0.00$0.00N/M vs Q2 2015 Gross Profit$4,127,447+67.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$91,315— Free Cash Flowderived-$305,887— Margins · derivedGross margin55.6%+15.1 pt vs Q2 2015
Operating margin5.0%+8.0 pt vs Q2 2015
Net margin-1.1%+4.1 pt vs Q2 2015
ended Jul 2, 2016 · filed Aug 11, 2016 · 40 d after period end